PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia

International Immunopharmacology

Volumn 8, Issue 12, 2008, Pages 1646-1651

  Tang, Yiting ^a,b   Lv, Ben ^a,b   Wang, Haichao ^c,d   Xiao, Xianzhong ^a   Zuo, Xiaoxia ^b  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Cytokine; Endotoxemia; HMGB1; Sepsis

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTOXEMIA; HUMAN; HUMAN CELL; LETHALITY; MALE; MEDIATOR RELEASE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVAL;

ANIMALS; CELLS, CULTURED; ENDOTOXEMIA; HMGB1 PROTEIN; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54549114416     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.07.014     Document Type: Article

References (35)

1. Lolis E., and Bucala R. Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat Rev Drug Discov 2 (2003) 635-645
2. Alleva L.M., Budd A.C., and Clark I.A. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 181 2 (2008) 1454-1459
3. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
4. Ulloa L., Ochani M., Yang H., Tanovic M., Halperin D., Yang R., et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99 (2002) 12351-12356
5. Hunter P. Sepsis under siege: a new understanding of sepsis might lead to the development of therapies to treat septic shock. EMBO Rep 7 7 (2006) 667-669
6. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101 (2004) 296-301
7. Huston J.M., Gallowitsch-Puerta M., Ochani M., Ochani K., Yuan R., Rosas-Ballina M., et al. Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 35 12 (2007) 2799-2804
8. van Zoelen M.A., Laterre P.F., van Veen S.Q., van Till J.W., Wittebole X., Bresser P., et al. Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 35 12 (2007) 2799-2804
9. Sundén-Cullberg J., Norrby-Teglund A., Rouhiainen A., Rauvala H., Herman G., Tracey K.J., et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33 3 (2005) 564-573
10. Ueno H., Matsuda T., Hashimoto S., Amaya F., Kitamura Y., Tanaka M., et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170 (2004) 1310-1316
11. Fink M.P. Bench-to-bedside review: high-mobility group box 1 and critical illness. Crit Care 11 5 (2007) 229
12. Gomariz R.P., Martinez C., Abad C., Leceta J., and Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 7 (2001) 89-111
13. Delgado M., Pozo D., Martinez C., Leceta J., Calvo J.R., Ganea D., et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol 162 (1999) 2358-2367
14. Delgado M., Martinez C., Pozo D., Calvo J.R., Leceta J., Ganea D., et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol 162 (1999) 1200-1205
15. Rendon-Mitchell B., Ochani M., Li J., Han J., Wang H., Yang H., et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170 (2003) 3890-3897
16. Yin K., Gribbin E., and Wang H. Interferon-gamma inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock 24 (2005) 396-401
17. Pahuja M., Tran C., Wang H., and Yin K. Alveolar macrophage suppression in sepsis is associated with high mobility group box 1 transmigration. Shock 29 6 (2008 Jun) 754-760
18. Eskandari M.K., Bolgos G., Miller C., Nguyen D.T., DeForge L.E., and Remick D.G. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148 (1992) 2724-2730
19. Osuchowski M.F., Welch K., Siddiqui J., and Remick D.G. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177 (2006) 1967-1974
20. Heuer J.G., Sharma G.R., Gerlitz B., Zhang T., Bailey D.L., et al. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit Care Med 32 (2004) 1570-1578
21. Vyas D., Javadi P., Dipasco P.J., Buchman T.G., Hotchkiss R.S., et al. Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am J Physiol Regul Integr Comp Physiol 289 (2005) R1048-1053
22. Wang H., Liao H., Ochani M., Justiniani M., Lin X., Yang L., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10 (2004) 1216-1221
23. Li W., Li J., Ashok M., Wu R., Chen D., Yang L., et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 178 (2007) 3856-3864
24. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192 (2000) 565-570
25. Abraham E., Arcaroli J., Carmody A., Wang H., and Tracey K.J. HMG-1 as a mediator of acute lung inflammation. J Immunol 165 (2000) 2950-2954
26. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26 (2006) 174-179
27. Chorny A., and Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 172 (2008) 1297-1307
28. Lv B, Tang YT, Chen FP, Xiao X.Z. VIP and PACAP inhibit tissue factor expression in monocyte in vitro and in vivo. Shock in press [2008, Electronic publication ahead of print].
29. Delgado M., Munoz-Elias E.J., Gomariz R.P., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 162 (1999) 1707-1716
30. El Zein N., Corazza F., and Sariban E. The neuropeptide pituitary adenylate cyclase activating protein is a physiological activator of human monocytes. Cell Signal 18 (2006) 162-173
31. El Zein N., Badran B.M., and Sariban E. The neuropeptide pituitary adenylate cyclase activating protein stimulates human monocytes by transactivation of the Trk/NGF pathway. Cell Signal 19 (2007) 152-162
32. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7 (2001) 563-568
33. Delgado M., Abad C., Martinez C., Juarranz M.G., Arranz A., Gomariz R.P., et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 80 (2002) 16-24
34. Taniguchi N., Kawahara K., Yone K., Hashiguchi T., Yamakuchi M., Goto M., et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48 (2003) 971-981
35. Mantell L.L., Parrish W.R., and Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25 (2006) 4-11